1031367-64-2Relevant articles and documents
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro
Salaroglio, Iris Chiara,Gazzano, Elena,Kopecka, Joanna,Chegaev, Konstantin,Costamagna, Costanzo,Fruttero, Roberta,Guglielmo, Stefano,Riganti, Chiara
, (2018)
P-glycoprotein (Pgp) determines resistance to a broad spectrum of drugs used against glioblastoma multiforme (GB). Indeed, Pgp is highly expressed in GB stem cells and in the brain-blood barrier (BBB), the peculiar endothelium surrounding the brain. Inhib
Comparison of in vitro assays in selecting radiotracers for in vivo P-glycoprotein PET imaging
Raaphorst, Renske M.,Savolainen, Heli,Cantore, Mariangela,van de Steeg, Evita,van Waarde, Aren,Colabufo, Nicola A.,Elsinga, Philip H.,Lammertsma, Adriaan A.,Windhorst, Albert D.,Luurtsema, Gert
, (2017/10/17)
Positron emission tomography (PET) imaging of P-glycoprotein (P-gp) in the blood-brain barrier can be important in neurological diseases where P-gp is affected, such as Alzheimer’s disease. Radiotracers used in the imaging studies are present at very smal
6,7-DIOXYALKYLTETRAHYDROISOQUINOLINE COMPOUNDS
-
, (2016/08/03)
The present invention relates to a 6,7-dioxyalkyltetrahydroisoquinoline compound, or a salt or solvate thereof according to formula I: (formula I), (I) wherein R represents hydrogen or a fluorinated alkyl group, and R2 and R3 independently represents hydrogen or an alkyl group.